An expert panel has recommended Wegovy for treating MASH in India. The CDSCO committee's decision could change how doctors manage progressive liver scarring. This shift moves treatment beyond simple lifestyle changes.
While the recommendation is a major step for regulatory approval, access remains uncertain. High costs for GLP-1 medications could still block many patients. The medical community is now waiting to see if this new use becomes a reality for the millions facing metabolic liver disease.
New use for Wegovy in India
An expert committee has recommended a new use for Wegovy in India. The Subject Expert Committee (SEC) on Endocrinology and Metabolism, which operates under the CDSCO[3], has proposed conditional approval for the drug. This move targets the treatment of Metabolic Dysfunction-Associated Steatohepatitis, commonly known as MASH.
This recommendation creates a new indication for the existing medication in the Indian market. The drug, a 2.4 mg Semaglutide injection, is marketed by Novo Nordisk India Private Limited. The panel's decision follows a detailed assessment of clinical data regarding how effectively the drug treats liver inflammation.
Millions of patients facing metabolic liver disease could see a shift in how they are treated. The approval is vital for managing liver diseases linked to obesity and metabolic disorders. It provides a new pharmaceutical tool for those struggling with progressive liver scarring.
Approval remains conditional.
The regulatory body will continue to monitor safety and efficacy data as the drug enters the market. This allows the medication to be used while the official oversight process remains active.
The shift in treatment approach
MASH is a progressive condition that can lead to liver scarring and failure. Existing treatment options in India have been limited to lifestyle changes and managing underlying metabolic issues. Wegovy, which contains semaglutide, targets the underlying metabolic drivers of the disease. Medical experts suggest this expansion could provide a much-needed pharmaceutical tool for early intervention.
What the panel decision means
The recommendation marks a critical step toward formal regulatory approval. The Subject Expert Committee (SEC) on Endocrinology and Metabolism reviewed the safety profile and clinical benefits of the drug specifically for MASH patients. This move aligns with global trends where GLP-1 receptor agonists are being repositioned for metabolic health.
This approval is conditional.
The SEC recommendation allows for conditional approval, meaning the drug can be marketed while the regulatory body continues to monitor safety and efficacy data. The CDSCO must still provide the final regulatory sign-off. This process ensures that the long-term impact of the 2.4 mg dose remains under scrutiny.
Availability in Indian pharmacies depends on this final step. Once the central licensing authority completes its review, the drug's presence in the supply chain will become clearer. The decision follows a broader shift in how doctors treat liver diseases linked to obesity and metabolic disorders.
Challenges for Indian patients
High costs for GLP-1 medications remain a primary barrier to access. While the drug offers a new way to manage liver inflammation, the price of semaglutide injections can be prohibitive for many families.
Access depends heavily on the Indian supply chain. The speed at which Wegovy reaches local pharmacies will dictate how quickly patients can begin treatment.
Doctors must also prepare for new clinical demands. Managing long-term use requires monitoring for side effects like nausea and gastrointestinal issues.
Scaling the infrastructure to track MASH progression is equally urgent. Healthcare providers need better tools to measure how the disease responds to these new pharmaceutical interventions.
There is a glimmer of hope for lower prices. India's semaglutide patent is expected to expire on 20 March[1].
After that date, about 50 branded generics are expected to enter the market. This influx of competition could eventually reshape the cost of obesity and metabolic care.
The next steps for regulation
Healthcare providers are watching for the formal inclusion of MASH in the drug's approved usage guidelines. Doctors need these official updates to change how they prescribe semaglutide for liver inflammation.
Pharmaceutical distributors are already preparing for potential changes in prescribing patterns. They are monitoring the regulatory timeline to adjust their supply chains for the new indication.
Official notification regarding the new indication is expected in the coming months.
The CDSCO central licensing authority must now review the panel's recommendations. This final review determines if the conditional approval moves forward. Official notification regarding the new indication is expected in the coming months.
